ClinicalTrials.gg
Not yet recruitingNCT07942194LANDMARK-ICUUpdated Nov 17, 2026

Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care

An observational study in Critical Illness, Traumatic Brain Injury and Subarachnoid Hemorrhage, sponsored by Fujian Provincial Hospital. Not yet recruiting at 6 sites in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionBrain Injuries, TraumaticRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Injuries, Traumatic
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Brain Injuries, Traumatic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fujian Provincial Hospital · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Brain Injuries, Traumatic with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Brain Injuries, Traumatic · China.

Planned enrollment
18th of 34
100 · median 110
Started
2026
with 3 others
Observational
34 of 60
19 open now
Primary completion
2027-12
later than 23 of 29 live
Registered
60th of 60
by date

Among the 60 studies in Brain Injuries, Traumatic with a site in China, this one is the 18th largest by planned enrollment of the 34 observational ones that give a count, is one of 4 that started in 2026, is one of 34 observational ones, reaches primary completion later than 23 of the 29 other live ones, and was the 60th registered.

Brain Injuries, Traumatic

1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

29 of the 60 studies in Brain Injuries, Traumatic with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Brain Injuries, Traumatic studies recruiting now, 123 (43%) set no upper age limit and 119 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Brain Injuries, Traumatic with a site in China, or all of them as a file.
02

Study summary

Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.

Read the detailed description

Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.

03

Conditions studied

  • Critical Illness
  • Traumatic Brain Injury
  • Subarachnoid Hemorrhage
  • Intracerebral Hemorrhage
  • Intracranial Hypertension
04

In context

Brain Injuries, Traumatic Reclassified

1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

This study's planned enrollment of 100 is below the median of 116 across 558 observational studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

Fujian Provincial Hospital is the lead sponsor of 41 studies on the registry; 23 are open to participants now.

Compared within Brain Injuries, Traumatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Continuous intracranial pressure monitoring for at least 24 hours
  • Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
  • Written from the patient or a legal representative

Exclusion criteria

Exclusion Criteria:

  • Incomplete or unusable intracranial pressure recordings
  • Loss to follow-up or unavailable outcome information
  • Pre-existing severe neurological disease that would confound assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)

Groups and cohorts

  • Neurocritical care cohort

    Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark.

    Diagnostic Test: Landmark machine learning mortality prediction model

Interventions

  • Diagnostic testLandmark machine learning mortality prediction model

    Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld.

07

What researchers measure

Primary outcomes

  1. Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark

    Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval

    Time frame: 24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

Secondary outcomes

  1. Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks

    Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals

    Time frame: 48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28

  2. Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks

    Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting.

    Time frame: 24, 48 and 72 hours after intensive care admission

  3. Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks

    Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance.

    Time frame: 24, 48 and 72 hours after intensive care admission

  4. Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score

    Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II

    Time frame: 24, 48 and 72 hours after intensive care admission

  5. Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark

    Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none

    Time frame: 24 hours after intensive care admission

  6. Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks

    Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small

    Time frame: 24, 48 and 72 hours after intensive care admission

  7. 28-day all-cause mortality, as specified in the approved protocol

    Time frame: 28 days after intensive care admission

  8. Length of intensive care stay

    Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care

    Time frame: From intensive care admission to intensive care unit discharge, up to 28 days

  9. Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months

    Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up

    Time frame: 6 months after intensive care admission

08

Study locations

6 sites
09

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 229 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 12 months is below that.

Counting every sponsor, half of 251 studies reached it within 49 months; a quarter within 23 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 12, 2027
CompletionEst.
Jan 1, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07942194
Lead sponsor
Fujian Provincial Hospital
Collaborators
Fuzhou University, Second Affiliated Hospital of Fujian Medical University, Hui'an County Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Shishi General Hospital
Responsible party
Han Chen (Associate Chief Physician, Fujian Provincial Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 12, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Han Chen, MD
principal investigator · Fujian Provincial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion